Document Detail

Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review.
MedLine Citation:
PMID:  24219102     Owner:  NLM     Status:  Publisher    
AIM: The use of topiramate, which is prescribed for the management of epilepsy, for migraine headache prophylaxis and as a weight-loss agent, has been associated with the development of metabolic acidosis, hypokalaemia and renal stone disease. We systematically reviewed all the literature.
METHODS: The systematic review of the literature was realized using the principles underlying the UK Economic and Social Research Council guidance on the conduct of narrative synthesis and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.
RESULTS: Fourty-seven reports published between 1996 and 2013 were retained for the final analysis. Five case-control studies and 6 longitudinal studies addressed the effect of topiramate on acid-base and potassium balance. A significant tendency towards mild to moderate hyperchloremic metabolic acidosis (with bicarbonate ≤21.0 mmol/L in approximately every third case) and mild hypokalaemia (with potassium ≤3.5 mmol/L in 10% of the cases) was noted on treatment with topiramate, which was similar in children and adults. A single study observed that topiramate causes mild hyperuricaemia in male adults. A tendency towards hypocitraturia, a recognized promoter of renal stone formation, was noted in all patients on topiramate.
CONCLUSIONS: Increasing evidence supports the use of topiramate. Topiramate is generally well tolerated and serious adverse events are rare. Nonetheless, the current systematic review of the literature indicates that its use is linked with the development of acidosis, hypokalaemia, hyperuricaemia and hypocitraturia.
Valentina G Dell'orto; Eva A Belotti; Barbara Goeggel-Simonetti; Giacomo D Simonetti; Gian Paolo Ramelli; Mario G Bianchetti; Sebastiano A G Lava
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-11-13
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  -     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-11-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
This article is protected by copyright. All rights reserved.
Integrated Department of Pediatrics, Ente Ospedaliero Cantonale Ticinese, and University of Berne, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Evidentiary Value of Challenge Trials for Three Pre-harvest Food Safety Topics: A Systematic Ass...
Next Document:  Four-and-a-half LIM domains proteins are novel regulators of the protein kinase D pathway in cardiac...